Quarterly report pursuant to Section 13 or 15(d)

Acquisition (Narrative) (Details)

v3.5.0.2
Acquisition (Narrative) (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Sep. 12, 2016
Sep. 30, 2016
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Business Acquisition [Line Items]            
Net loss     $ 1,709,932 $ 1,583,084 $ 1,986,296 $ 5,802,692
BiOptix [Member]            
Business Acquisition [Line Items]            
Percentage of outstanding voting stock owned by parent 98.00%          
Percentage of Venaxis common stock issued as equity consideration 14.00%          
Annual estimated future amortization for acquired finite-lived intangible assets $ 460,000          
Revenue   $ 1,900        
Net loss   107,000        
Advisory and legal fees related to the acquisition   106,000 106,000   106,000  
Inventories raw materials acquired   118,734 118,734   118,734  
Inventories work in process acquired   27,553 27,553   27,553  
Inventories finished goods acquired   $ 265,819 $ 265,819   $ 265,819  
BiOptix [Member] | Minimum [Member]            
Business Acquisition [Line Items]            
Average life of intangible assets acquired 4 years          
BiOptix [Member] | Maximum [Member]            
Business Acquisition [Line Items]            
Average life of intangible assets acquired 6 years          
BiOptix [Member] | Common Stock [Member]            
Business Acquisition [Line Items]            
Equity consideration issued for acquisition, number of shares 627,010          
Value of equity consideration issued for acquisition $ 2,577,000